Loading Events

« All Events

Lupus Ontario Symposium 2024 – Redefining The Lupus Landscape

October 22, 2024 @ 7:00 pm October 23, 2024 @ 9:00 pm

SESSION 1: 22nd October, 7-8PM EST,

EULAR Guideline Revisions

In this session, Dr. Laura Whitthall Garcia will delve into the European Alliance of Associations for Rheumatology (EULAR) and its crucial role in setting guidelines for lupus. She will discuss the current EULAR guidelines for lupus, recent changes to these guidelines, and the reasons behind these updates. Additionally, the session will explore how these guidelines are applied in diagnosing and treating lupus to ensure effective and standardized patient care.

SESSION 2: 22nd October, 8-9PM EST

Lupus Types Expanded

In this session, Dr. Murray Urowitz will provide a brief recap of Types 1 and 2 lupus, followed by an in-depth exploration of lupus types 3, 4, and beyond. He will discuss the implications of these classifications on ongoing lupus patient treatment and provide insights on how patients can effectively advocate for themselves as their disease evolves. The session aims to equip lupus patients with the knowledge and strategies to engage proactively with their care practitioners.

SESSION 3: 23rd October, 7-8PM EST

Biologics Explained

In this session, Dr. Amanda Steiman will demystify biologics by explaining what they are and how they function in treating diseases. She will highlight the differences between biologics and other treatment options, detailing how patients should prepare for biologic treatment, including necessary tests, vaccines, and potential side effects. Additionally, Dr. Steiman will compare infusion and subcutaneous methods, providing guidance on what patients can expect from each approach.

SESSION 4: 23rd October, 8-9PM EST

CAR T-Cell Therapy and Upcoming Treatments

In this session, Dr. Mark Matsos will provide an overview of emerging treatments for lupus, with a focus on CAR T-Cell Therapy. He will explain the fundamentals of CAR T-Cell Therapy and discuss how this innovative approach could revolutionize the treatment landscape for lupus patients. The session will offer a glimpse into the future of lupus care, highlighting the potential benefits and transformative impact of these new therapies.


Sign the petition and MAKE A DIFFERENCE!

This Lupus Ontario petition is advocating to have the Ontario government approve all biologics approved by the Federal Health Agency (CADTH) added to the Ontario Drug Formulary under the Limited Use code rather that the Exceptional Access Program. The Limited Use code eliminates the administrative burden for rheumatologists and provides faster access for lupus patients. Please print and gather signatures and send it to our address: 285 Taunton Road East, Suite 4438, Oshawa, ON  L1G 3V2 Canada